Next Article in Journal
The Current Use of Stem Cells in Bladder Tissue Regeneration and Bioengineering
Next Article in Special Issue
Targeting Autophagy for Oncolytic Immunotherapy
Previous Article in Journal / Special Issue
Viroimmunotherapy of Thoracic Cancers
Article Menu

Export Article

Open AccessFeature PaperReview
Biomedicines 2017, 5(1), 3; doi:10.3390/biomedicines5010003

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies

1
Ottawa Hospital Research Institute, Center for Cancer Therapeutic, Ottawa, ON K1H 8L6, Canada
2
Department of Biochemistry, Microbiology and Immunology, Ottawa, ON K1H 8M5, Canada
*
Author to whom correspondence should be addressed.
Academic Editors: Zong Sheng Guo and David L. Bartlett
Received: 27 November 2016 / Revised: 20 December 2016 / Accepted: 22 December 2016 / Published: 4 January 2017
(This article belongs to the Special Issue Oncolytic Viruses as a Novel Form of Immunotherapy for Cancer)
View Full-Text   |   Download PDF [259 KB, uploaded 4 January 2017]   |  

Abstract

Vaccines have classically been used for disease prevention. Modern clinical vaccines are continuously being developed for both traditional use as well as for new applications. Typically thought of in terms of infectious disease control, vaccination approaches can alternatively be adapted as a cancer therapy. Vaccines targeting cancer antigens can be used to induce anti-tumour immunity and have demonstrated therapeutic efficacy both pre-clinically and clinically. Various approaches now exist and further establish the tremendous potential and adaptability of anti-cancer vaccination. Classical strategies include ex vivo-loaded immune cells, RNA- or DNA-based vaccines and tumour cell lysates. Recent oncolytic virus development has resulted in a surge of novel viruses engineered to induce powerful tumour-specific immune responses. In addition to their use as cancer vaccines, oncolytic viruses have the added benefit of being directly cytolytic to cancer cells and thus promote antigen recognition within a highly immune-stimulating tumour microenvironment. While oncolytic viruses are perfectly equipped for efficient immunization, this complicates their use upon previous exposure. Indeed, the host’s anti-viral counter-attacks often impair multiple-dosing regimens. In this review we will focus on the use of oncolytic viruses for anti-tumour vaccination. We will explore different strategies as well as ways to circumvent some of their limitations. View Full-Text
Keywords: oncolytic virus; vaccination strategy; cancer; immunotherapy; immunization; tumour-associated antigen; prime-boost; novel therapy oncolytic virus; vaccination strategy; cancer; immunotherapy; immunization; tumour-associated antigen; prime-boost; novel therapy
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Aitken, A.S.; Roy, D.G.; Bourgeois-Daigneault, M.-C. Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines 2017, 5, 3.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top